168 related articles for article (PubMed ID: 37793852)
21. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Shen S; Chen X; Cai J; Yu J; Gao J; Hu S; Zhai X; Liang C; Ju X; Jiang H; Jin R; Wu X; Wang N; Tian X; Pan K; Jiang H; Sun L; Fang Y; Li CK; Hu Q; Yang M; Zhu Y; Zhang H; Li C; Pei D; Jeha S; Yang JJ; Cheng C; Tang J; Zhu X; Pui CH
JAMA Oncol; 2020 Mar; 6(3):358-366. PubMed ID: 31944221
[TBL] [Abstract][Full Text] [Related]
22. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Appelmann I; Rillahan CD; de Stanchina E; Carbonetti G; Chen C; Lowe SW; Sherr CJ
Blood; 2015 Feb; 125(9):1444-51. PubMed ID: 25499760
[TBL] [Abstract][Full Text] [Related]
23. CBP Modulates Sensitivity to Dasatinib in Pre-BCR
Duque-Afonso J; Lin CH; Han K; Morgens DW; Jeng EE; Weng Z; Jeong J; Wong SHK; Zhu L; Wei MC; Chae HD; Schrappe M; Cario G; Duyster J; Xiao X; Sakamoto KM; Bassik MC; Cleary ML
Cancer Res; 2018 Nov; 78(22):6497-6508. PubMed ID: 30262461
[TBL] [Abstract][Full Text] [Related]
24. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
25. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
26. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts.
Ganguly S; Sasi A; Pushpam D; Bakhshi S
Indian J Pediatr; 2024 Jan; 91(1):37-46. PubMed ID: 37632689
[TBL] [Abstract][Full Text] [Related]
27. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
Mustafa Ali MK; Sabha MM; Al-Rabi KH
Platelets; 2015; 26(5):491-4. PubMed ID: 25025538
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
Fraser CK; Blake SJ; Diener KR; Lyons AB; Brown MP; Hughes TP; Hayball JD
Exp Hematol; 2009 Feb; 37(2):256-65. PubMed ID: 19056158
[TBL] [Abstract][Full Text] [Related]
29. Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib.
Liu G; Jin Z; Lu X
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230980
[TBL] [Abstract][Full Text] [Related]
30. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
31. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of efficacy of first-line administration of generic dasatinib or imatinib in patients with Philadelphia chromosome positive acute lymphoblastic leukemia treated by hematopoietic stem cell transplantation].
Yang F; Cai WZ; Huang XW; Xue SL; Fu CC; Tang XW; Sun AN; Wu DP; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):661-667. PubMed ID: 30180468
[No Abstract] [Full Text] [Related]
33. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
[TBL] [Abstract][Full Text] [Related]
34. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
35. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.
Nagasaki J; Togashi Y; Sugawara T; Itami M; Yamauchi N; Yuda J; Sugano M; Ohara Y; Minami Y; Nakamae H; Hino M; Takeuchi M; Nishikawa H
Blood Adv; 2020 Sep; 4(17):4069-4082. PubMed ID: 32870971
[TBL] [Abstract][Full Text] [Related]
36. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
[TBL] [Abstract][Full Text] [Related]
37. Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib.
Sekimizu M; Yamashita Y; Ueki H; Akita N; Hattori H; Maeda N; Horibe K
Leuk Lymphoma; 2014 Jul; 55(7):1652-3. PubMed ID: 24024475
[No Abstract] [Full Text] [Related]
38. Donor programmed cell death 1 ligand 1 is required for organ transplant tolerance in major histocompatibility complex-mismatched mixed chimeras although programmed cell death 1 ligand 1 and major histocompatibility complex class II are not required for inducing chimerism.
Huang Y; Wu X; Tang S; Wu H; Nasri U; Qin Q; Song Q; Wang B; Tao H; Chong AS; Riggs AD; Zeng D
Am J Transplant; 2023 Aug; 23(8):1116-1129. PubMed ID: 37105316
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Aldoss I; Gaal K; Al Malki MM; Ali H; Nakamura R; Forman SJ; Pullarkat V
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1900-1903. PubMed ID: 27346662
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sugiura I; Doki N; Hata T; Cho R; Ito T; Suehiro Y; Tanaka M; Kako S; Matsuda M; Yokoyama H; Ishikawa Y; Taniguchi Y; Hagihara M; Ozawa Y; Ueda Y; Hirano D; Sakura T; Tsuji M; Kamae T; Fujita H; Hiramoto N; Onoda M; Fujisawa S; Hatta Y; Dobashi N; Nishiwaki S; Atsuta Y; Kobayashi Y; Hayakawa F; Ohtake S; Naoe T; Miyazaki Y
Blood Adv; 2022 Jan; 6(2):624-636. PubMed ID: 34516628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
